Literature DB >> 26116477

Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia.

Takahiro Omori1, Michihiko Tajiri2, Tomohisa Baba3, Takashi Ogura3, Tae Iwasawa4, Koji Okudela5, Tamiko Takemura6, Mari S Oba7, Takamitsu Maehara8, Haruhiko Nakayama9, Masahiro Tsuboi10, Munetaka Masuda11.   

Abstract

BACKGROUND: After pulmonary resection, patients with lung cancer who have idiopathic pulmonary fibrosis (IPF) have been reported to have higher pulmonary morbidity and mortality and poorer outcomes than patients without IPF. However, whether morbidity, mortality, and outcomes differ according to the subtype of idiopathic interstitial pneumonia (IIP) remains unclear.
METHODS: The clinical records of 678 patients with non-small cell lung cancer who underwent pulmonary resection were reviewed retrospectively. A total of 103 patients had IIP and were classified into an IPF group and a non-IPF group in accordance with the 2011 statement.
RESULTS: The IPF group comprised 46 patients, and the non-IPF group comprised 57. The 5-year survival rate was significantly higher in the non-IPF group (53.2%) than in the IPF group (22.1%; p = 0.0093). Cause of death was IIP-related respiratory failure in 26.1% (12 of 46) of the patients in the IPF group as compared with 7.0% (4 of 57) of patients in the non-IPF group (p = 0.008). Multivariate Cox analysis indicated that IPF was a significant predictor of long-term survival (hazard ratio 1.910, 95% confidence interval: 1.102 to 3.313; p = 0.021).
CONCLUSIONS: Idiopathic pulmonary fibrosis is independently associated with poorer overall survival in patients with lung cancer who undergo pulmonary resection. The decision whether to perform surgery in patients who have lung cancer with IIP should therefore take into account the subtype of IIP and the poorer outcomes associated with IPF.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26116477     DOI: 10.1016/j.athoracsur.2015.03.094

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  23 in total

Review 1.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Extraction of the subpleural lung region from computed tomography images to detect interstitial lung disease.

Authors:  Tae Iwasawa; Yuma Iwao; Tamiko Takemura; Koji Okudela; Toshiyuki Gotoh; Tomohisa Baba; Takashi Ogura; Mari S Oba
Journal:  Jpn J Radiol       Date:  2017-09-21       Impact factor: 2.374

3.  The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.

Authors:  Naoki Nishiyama; Takayuki Honda; Manabu Sema; Tatsuo Kawahara; Yasuto Jin; Ichiro Natsume; Tomoshige Chiaki; Takaaki Yamashita; Yoshikazu Tsukada; Reiko Taki; Yoshihiro Miyashita; Kazuhito Saito; Tomoya Tateishi; Hiroyuki Sakashita; Yasunari Miyazaki
Journal:  Int J Clin Oncol       Date:  2019-11-13       Impact factor: 3.402

4.  Outcomes of Older Patients with Pulmonary Fibrosis and Non-Small Cell Lung Cancer.

Authors:  Stacey-Ann Whittaker Brown; Maria Padilla; Grace Mhango; Emanuela Taioli; Charles Powell; Juan Wisnivesky
Journal:  Ann Am Thorac Soc       Date:  2019-08

Review 5.  Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy.

Authors:  Xiuqiong Chen; Zhaona Li; Xinyue Wang; Jing Zhou; Qianhui Wei; Richeng Jiang
Journal:  Support Care Cancer       Date:  2022-04-11       Impact factor: 3.603

6.  Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.

Authors:  Kenji Sawa; Izumi Sato; Masato Takeuchi; Koji Kawakami
Journal:  Cancer Immunol Immunother       Date:  2022-08-22       Impact factor: 6.630

7.  Real world data of combined lung cancer and interstitial lung disease.

Authors:  Tatsuo Kawahara; Hiroyuki Sakashita; Takafumi Suzuki; Tomoya Tateishi; Yasunari Miyazaki
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 8.  Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management.

Authors:  Justin M Oldham; Harold R Collard
Journal:  Front Med (Lausanne)       Date:  2017-08-02

9.  A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).

Authors:  Takekazu Iwata; Ichiro Yoshino; Shigetoshi Yoshida; Norihiko Ikeda; Masahiro Tsuboi; Yuji Asato; Nobuyuki Katakami; Kazuhiro Sakamoto; Yoshinori Yamashita; Jiro Okami; Tetsuya Mitsudomi; Motohiro Yamashita; Hiroshi Yokouchi; Kenichi Okubo; Morihito Okada; Mitsuhiro Takenoyama; Masayuki Chida; Keisuke Tomii; Motoki Matsuura; Arata Azuma; Tae Iwasawa; Kazuyoshi Kuwano; Shuji Sakai; Kenzo Hiroshima; Junya Fukuoka; Kenichi Yoshimura; Hirohito Tada; Kazuhiko Nakagawa; Yoichi Nakanishi
Journal:  Respir Res       Date:  2016-07-22

10.  Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis.

Authors:  Mio Nakajima; Naoyoshi Yamamoto; Kazuhiko Hayashi; Masataka Karube; Daniel K Ebner; Wataru Takahashi; Makoto Anzai; Kenji Tsushima; Yuji Tada; Koichiro Tatsumi; Tadaaiki Miyamoto; Hiroshi Tsuji; Takehiko Fujisawa; Tadashi Kamada
Journal:  Radiat Oncol       Date:  2017-09-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.